Frontiers in Immunology · 2020 · 31 citations · 46 references
MedicineImmunologyNeuroscienceInflammationNeuroimmunologyOcular ImmunologyImmunopathology Of The EyeMicroglia BiologyNeuroinflammationOcular InflammationRetinal ImmunologyRetinal NeurobiologyColony-stimulating Factor 1 Receptor TargetingColony-stimulating Factor 1 SignalingPro-inflammatory Cytokine CascadesRetinal Glial ResponsesRetinal Immune ResponsesRetinal MicrogliaRetinal NeuroinflammationVisual Function Loss
Retinal ischemia/reperfusion injury (RI) is a common cause of irreversible visual impairment and blindness in elderly and critical unmet medical need. While no effective treatment is available for RI, microglial activation and local immune responses in the retina are thought to play important roles in the pathophysiology of neurodegeneration. While survival and activation of microglia depend critically on colony-stimulating factor receptor (CSF-1R) signaling, it remains unclear if targeting the retinal immune microenvironments by CSF-1RAb after RI is sufficient to rescue vision and present a potentially effective therapy. Here we used rodent models of RI and showed that retinal ischemia induced by acute elevation of intraocular pressure triggered an early activation of microglia and macrophages in the retina within 12 h. This was followed by lymphocyte infiltration and increased production of pro-inflammatory cytokines. Intravitreal injection of CSF-1R neutralizing antibody (CSF-1RAb) after RI significantly blocked microglial activation and the subsequent T cell recruitment. This also led to improved retinal ganglion cell survival and function measured by cell quantification and electroretinogram positive scotopic threshold responses, as well as increased visual acuity and contrast sensitivity as assessed by optomotor reflex-based assays, when compared to the isotype-treated control group. Moreover, the administration of CSF-1RAb efficiently attenuated inflammatory responses and activation of human microglia in culture, suggesting a therapeutic target with human relevance. These results, together with the existing clinical safety profiles, support that CSF-1RAb may present a promising therapeutic avenue for RI, a currently untreatable condition, by targeting microglia and the immune microenvironment in the retina to facilitate neural survival and visual function recovery.
46
Neurotoxic reactive astrocytes are induced by activated microglia
Shane A. Liddelow, Kevin A. Guttenplan, Laura Clarke et al. · Nature · 2017 · 8K citations · Full text
Medicine, Neurobiology, Neuroscience +14
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Florent Ginhoux, Melanie Greter, Marylène Leboeuf et al. · Science · 2010 · 5.1K citations · Full text